Abstract:Duchenne muscular dystrophy (DMD) results from mutations in the largest known gene, dystrophin. Gene therapy for DMD will require methods to systemically deliver a therapeutic dystrophin gene to widely distributed muscles. Recent observations indicating that vascularly transplanted adult stem cells can home and become muscle cells in an appropriate micro-environment has suggested one possible method for delivering genes to muscle. A smaller, easily traceable, and functional dystrophin would facilitate experiments aimed at improving ex vivo cell-based strategies. We previously found that large portions of the dystrophin central rod domain (Hinge 2 to Repeat 19) and the C-terminal domain (encoded on exons 71 to Exon 78) are not essential for the full function of dystrophin, as assayed by the ability to prevent and partially reverse morphological and fucnional abnormalities in mdx mouse skeletal muscles. Here, we engineered a 5.7-kb MiniDys-eGFP fusion gene by replacing the C-terminal domain of mini-dystrophin (DH2-R19) with an enhanced green fluorescence gene coding sequence and by trimming down the size of 5' and 3' UTR of dystrophin. This fusion gene can be inserted into lentiviral vectors and efficiently delivered into a variety of cell types in vitro. This MiniDys-eGFP fusion protein was found to fully prevent dystrophy of multiple skeletal muscles in transgenic mdx mice carrying the fusion gene under the control of the human a-skeletal actin (HSA) gene promoter. This green fusion protein was easily observed by fluorescence microscopy on the sarcolemma of skeletal muscle fibers of the transgenic mdx mice. Furthermore, donor-derived GFP-positive myofibers were detected in mdx recipient muscles transplanted with either whole bone marrow cells or primary myoblasts isolated from the MiniDys-eGFP transgenic mice. These data indicate that the smaller, easily traceable, and functional MiniDys-eGFP will be useful for developing ex vivo cell-based gene therapies for DMD.

37. Long-Term Expression of Mini-Human Dystrophin in Transgenic mdx Mice Improves Dystrophic Muscle Functions

Long-term Effect of Human Mini-Dystrophin in Transgenic Mdx Mice Improves Muscle Physiological Function.

Research Progress on Disease Models and Gene Therapy of Duchenne Muscular Dystrophy

Cardiac-Specific Expression of ΔH2-R15 Mini-Dystrophin Normalized All Electrocardiogram Abnormalities and the End-Diastolic Volume in a 23-Month-Old Mouse Model of Duchenne Dilated Cardiomyopathy

Molecular Pathogenesis of Genetic and Inherited Diseases Preservation of Muscle Force in Mdx3cv Mice Correlates with Low-Level Expression of a Near Full-Length Dystrophin Protein

Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.

242. A Novel MiniDys-eGFP Fusion Gene for Developing Cell-Based Therapies of Duchenne Muscular Dystrophy

Abstract 3808: AAV-9 Micro-Dystrophin Gene Therapy Halts Heart Disease Progression in Symptomatic Dystrophic Mice

Restoration of Muscle Fibers and Satellite Cells after Isogenic MSC Transplantation with Microdystrophin Gene Delivery.

Humanizing the mdx mouse model of DMD: the long and the short of it

Preservation of Muscle Force in Mdx3cv Mice Correlates with Low-Level Expression of a Near Full-Length Dystrophin Protein

The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology

Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy

Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model

Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice

Behavioral, Biochemical and Pathological Characterization of a New MDX Mouse Model of Duchenne Muscular Dystrophy

Mitochondrial Transplantation Therapy Ameliorates Muscular Dystrophy in mdx Mouse Model

Marginal Level Dystrophin Expression Improves Clinical Outcome In A Strain Of Dystrophin/Utrophin Double Knockout Mice

Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin-Deficient D2.B10-Dmd mdx /J Mouse

Respiratory Characterization of a Humanized Duchenne Muscular Dystrophy Mouse Model

Abstract 44: Telomere and Mitochondrial Dysfunction in Duchenne Muscular Dystrophy